Societal CDMO

Societal CDMO (SCTL) is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a CDMO division.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Societal CDMO balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Societal CDMO cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Societal CDMO multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Societal CDMO profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Societal CDMO assets
Societal CDMO cash flows
Societal CDMO news
12.05.2022
Societal CDMO's GAAP loss for 3 months of 2022 was $4.3 million, down 36.8% from $6.8 million in the previous year. Revenue increased by 26.2% to $21.2 million compared to $16.8 million a year earlier.
Source: ir.recropharma.com pictogram ir.recropharma.com
Pictogram next
21.03.2022
Recro Pharma changed its name to Societal CDMO. The rebranding was done to reflect the corporate transformation resulting from the acquisition and successful integration of IriSys. As of March 22, 2022, Societal CDMO will begin trading under the SCTL symbol.
Source: ir.recropharma.com pictogram ir.recropharma.com
Pictogram next
02.03.2022
Recro Pharma's GAAP loss for 2021 was $11.37 million, down 2.6 times from $27.501 million in the previous year. Revenue increased 13.3% to $75.36 million from $66.499 million a year earlier.
Source: ir.recropharma.com pictogram ir.recropharma.com
Pictogram next
10.11.2021
Recro Pharma's GAAP loss for 9M 2021 was $9.013 million, down 43.1% from $15.831 million in the previous year. Revenue decreased 6.2% to $53.057 million from $56.586 million a year earlier.
Source: recrocdmo.com pictogram recrocdmo.com
Pictogram next
All Societal CDMO news
General information
Company nameSocietal CDMO
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address490 LAPP ROAD MALVERN PA 19355 (484) 395-2400
Mailing address490 LAPP ROAD MALVERN PA 19355
Websitewww.recropharma.com
Information disclosurewww.sec.gov